GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and
only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
( Total: 23 Current Stock Recommendations )
Alkermes, Inc.   (23)
Sell Hold 43% Buy 43%
Related companies
China Biologic ...   (4)
Buy 100%
Opko Health Inc   (2)
Buy 100%
Talecris ...   (4)
Buy 100%
Anacor ...   (6)
Buy 100%
Santarus, Inc.   (13)
Hold 31% Buy 69%
Cardinal Health, ...   (24)
Hold 29% Buy 71%
Incyte Corporation   (22)
Sell Hold Buy 82%
Nbty, Inc.   (9)
Hold 44% Buy 56%
Dr. Reddy's ...   (5)
Sell 20% Hold 40% Buy 40%
Salix ...   (31)
Hold 39% Buy 61%
Filter by Gains:   
  
Rating:
Sell ALKS
Alkermes, Inc. (ALKS) downgraded to Underweight by Morgan Stanley
Thursday,  Jan 21, 2016  5:25 PM ET

Rating:
Hold ALKS
Alkermes, Inc. (ALKS) downgraded to Neutral by JP Morgan
Thursday,  Jan 21, 2016  5:25 PM ET

Rating:
Buy ALKS
up 65.19 %

Rating:
Buy ALKS

Rating:
Buy ALKS
down 0.22 %

Rating:
Buy ALKS
up 43.05 %
Alkermes, Inc. (ALKS) rated Buy with price target $59 by Mizuho
Thursday,  Jul 31, 2014  12:00 AM ET

Rating:
Buy ALKS
up 41.95 %

Rating:
Sell ALKS
down 44.67 %

Rating:
Hold ALKS
Alkermes, Inc. (ALKS) rated Neutral with price target $53 by UBS
Friday,  Feb 28, 2014  11:25 AM ET

Rating:
Hold ALKS

Rating:
Hold ALKS
up 19.76 %

Rating:
Hold ALKS

Rating:
Hold ALKS

Rating:
Hold ALKS

Rating:
Buy ALKS
up 79.75 %
Alkermes, Inc. (ALKS) rated Outperform by Leerink Swann
Wednesday,  May 29, 2013  8:25 AM ET

Your Recent Stocks
SymbolLastChange
ALKS 33.71 down  -44.89 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy